Tag Directory / DIABETES     showing 1–1 of 1   RSS


for: Wednesday, April 22, 2026



CMS delays Part D GLP-1 model amid skepticism from insurers

fiercehealthcare - The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers.

AI Summary: Federal regulators have paused a Medicare Part D pilot to expand coverage for GLP‑1 weight‑loss drugs amid payer skepticism and implementation concerns. The delay reflects worries about cost, program design and insurer buy‑in, forcing policymakers to revisit the model while patients and providers wait for clarity on whether Medicare will shoulder these high‑price therapies.


CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback

2 months / medicalxpress

2 months / fiercehealthcare


Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress


Telehealth and clinics scale GLP‑1 access, delivery and monitoring

2 months / fiercehealthcare

2 months / fiercehealthcare


All Other Stories

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

2 months / discovermagazine

2 months / fiercehealthcare

2 months / medicalxpress

2 months / medicalxpress

2 months / livescience

2 months / medicalxpress

2 months / medicalxpress




Back to Top


DIABETES Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Gene Therapy, Vitamin D, Supply Chain, Adolescent Health and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.